PARP1 and lip and oral cavity carcinoma: Considering the crucial role of olaparib, our findings could provide a new therapeutic strategy for oral carcinoma—especially for neoadjuvant chemotherapy to prevent microinvasion, local recurrence, and metastasis to other organs via regulation of the EMT/MET pathway—and aid the examination of current PARP inhibitors for bone metastasis and bone loss.